Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

General Updates | Drugs under investigation for patients with MF who have failed treatment with JAK inhibitors

Jean-Jacques Kiladjian • 16 May 2022
General Updates
Myelofibrosis Myeloproliferative Neoplasms Imetelstat Navitoclax Navtemadlin Parsaclisib Pelabresib Ruxolitinib

Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, gives an overview of agents that are currently being evaluated in patients with myelofibrosis (MF) who have failed treatment with JAK inhibitors, including parsaclisib, pelabresib, navitoclax, imetelstat, and navtedmadlin. This interview took place virtually.

Disclosures

Advisory boards for Novartis, Abbvie, BMS, AOP Orphan.

More from Jean-Jacques Kiladjian

16:35
Key highlights in MPNs at ASH 2023: novel agents & combinations, ongoing clinical trials, and more
Claire Harrison et al. • 11 Dec 2023
2:31
The growing role of combination approaches in MF & agents being explored
Jean-Jacques Kiladjian • 9 Oct 2023
4:35
The role of JAK2 VAF testing in risk assessment and disease monitoring in MPNs
Jean-Jacques Kiladjian • 13 Jun 2023
2:14
Ruxolitinib combinations in patients with myelofibrosis
Jean-Jacques Kiladjian • 26 Apr 2023

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals